PH12014000244B1 - Method for the treatment of hypercholesterolemia - Google Patents

Method for the treatment of hypercholesterolemia Download PDF

Info

Publication number
PH12014000244B1
PH12014000244B1 PH12014000244A PH12014000244A PH12014000244B1 PH 12014000244 B1 PH12014000244 B1 PH 12014000244B1 PH 12014000244 A PH12014000244 A PH 12014000244A PH 12014000244 A PH12014000244 A PH 12014000244A PH 12014000244 B1 PH12014000244 B1 PH 12014000244B1
Authority
PH
Philippines
Prior art keywords
calebin
mammal
density lipoproteins
reducing
kcal
Prior art date
Application number
PH12014000244A
Other languages
English (en)
Other versions
PH12014000244A1 (en
Inventor
Muhammed Majeed
Kalyanam Nagabhushanam
Anju Majeed
Sarang Bani
Anjali Pandey
Original Assignee
Sami Labs Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sami Labs Ltd filed Critical Sami Labs Ltd
Publication of PH12014000244A1 publication Critical patent/PH12014000244A1/en
Publication of PH12014000244B1 publication Critical patent/PH12014000244B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/25—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PH12014000244A 2014-04-23 2014-08-26 Method for the treatment of hypercholesterolemia PH12014000244B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14/259,404 US9668999B2 (en) 2014-04-23 2014-04-23 Method for the treatment of hypercholesterolemia

Publications (2)

Publication Number Publication Date
PH12014000244A1 PH12014000244A1 (en) 2016-08-08
PH12014000244B1 true PH12014000244B1 (en) 2016-08-08

Family

ID=50828681

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12014000244A PH12014000244B1 (en) 2014-04-23 2014-08-26 Method for the treatment of hypercholesterolemia

Country Status (11)

Country Link
US (2) US9668999B2 (enExample)
EP (1) EP2937084B1 (enExample)
JP (1) JP6263707B2 (enExample)
KR (1) KR101647549B1 (enExample)
AU (1) AU2014202312B2 (enExample)
CA (2) CA2963383C (enExample)
EA (1) EA027148B1 (enExample)
MY (1) MY170067A (enExample)
PH (1) PH12014000244B1 (enExample)
PL (1) PL2937084T3 (enExample)
TW (1) TWI622394B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201503805XA (en) * 2015-04-19 2016-11-29 Sabinsa Corp Calebin A For Hepatic Steatosis
US9539232B1 (en) * 2016-08-04 2017-01-10 Muhammed Majeed Calebin A for osteoporosis

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1060352C (zh) * 1996-02-08 2001-01-10 袁克兴 降脂药及其制备方法
US6811786B1 (en) * 1999-04-01 2004-11-02 Ganeden Biotech, Inc. Methods for reducing cholesterol using Bacillus coagulans spores, systems and compositions
AU2300001A (en) * 1999-10-22 2001-05-08 Board Of Trustees Of The University Of Illinois, The Pharmaceutical compositions useful in the prevention and treatment of beta-amyloid protein-induced disease
US20020012733A1 (en) 2000-04-12 2002-01-31 The Procter & Gamble Company Compositions for reducing hypercholesterolemia and controlling of postprandial blood glucose and insulin levels
JP2005232059A (ja) * 2004-02-18 2005-09-02 Iichiro Shimomura 低アディポネクチン血症予防・治療剤
JP4834824B2 (ja) * 2004-07-08 2011-12-14 独立行政法人産業技術総合研究所 アディポネクチン産生増強剤
JP5294165B2 (ja) * 2007-03-23 2013-09-18 ナガセケムテックス株式会社 アディポネクチン上昇剤
JP2010018522A (ja) * 2007-03-23 2010-01-28 Hiroshima Univ アディポネクチン産生促進剤
CN101301455A (zh) * 2008-07-01 2008-11-12 崔井朝 一种治疗高脂血症的中药复方姜黄固体分散体
JP2011063543A (ja) * 2009-09-17 2011-03-31 Kao Corp アディポネクチン増加剤
WO2013109241A1 (en) * 2011-01-10 2013-07-25 Muhammed Majeed Anti-obesity potential of calebin a

Also Published As

Publication number Publication date
TWI622394B (zh) 2018-05-01
TW201540295A (zh) 2015-11-01
US20150306059A1 (en) 2015-10-29
CA2963383C (en) 2018-12-04
CA2850999C (en) 2018-04-03
KR101647549B1 (ko) 2016-08-10
AU2014202312A1 (en) 2015-11-12
PH12014000244A1 (en) 2016-08-08
EP2937084A1 (en) 2015-10-28
US9668999B2 (en) 2017-06-06
JP2015209424A (ja) 2015-11-24
CA2963383A1 (en) 2015-10-23
PL2937084T3 (pl) 2017-05-31
AU2014202312B2 (en) 2018-02-22
CA2850999A1 (en) 2015-10-23
JP6263707B2 (ja) 2018-01-24
EA027148B1 (ru) 2017-06-30
HK1210590A1 (en) 2016-04-29
EP2937084B1 (en) 2016-11-30
KR20150122552A (ko) 2015-11-02
EA201491545A1 (ru) 2015-10-30
US9610273B2 (en) 2017-04-04
US20150306060A1 (en) 2015-10-29
NZ624269A (en) 2014-12-24
MY170067A (en) 2019-07-03

Similar Documents

Publication Publication Date Title
Cardinali et al. Melatonin may curtail the metabolic syndrome: studies on initial and fully established fructose-induced metabolic syndrome in rats
Zhang et al. A preliminary study in immune response of BALB/c and C57BL/6 mice with a locally allergic rhinitis model
Kabadi Marked weight loss, muscle wasting and fatigue on administration of empagliflozin in a subject with type 2 diabetes
Malvindi et al. The enhanced recovery after surgery approach in heart valve surgery: a systematic review of clinical studies
US9610273B2 (en) Method for the treatment of hypercholesterolemia
Kroll et al. Additional assessment of fecal corticosterone metabolites improves visual rating in the evaluation of stress responses of laboratory rats
Galosi et al. Comparison of the transdermal and intravenous administration of buprenorphine in the management of intra-and postoperative pain in dogs undergoing a unilateral mastectomy
Straticò et al. Analgesic effect of Butorphanol during Castration in Donkeys under total intravenous anaesthesia
Recchia et al. The Pharmacological Class Alpha 2 Agonists for Stress Control in Patients with Respiratory Failure: The Main Actor in the Different Acts
Michael Adaptation to Brief Stress: The Blood Level of Leucocytes and Adrenal Function in Epilepsy, Electrically Induced Convulsions, and after Injection of Epinephrine
Mirtha et al. The effect of foot exercise on diabetic patients with foot ulcer: An Evidence-based case report
Buchholz et al. Transdermal fentanyl uptake at two different patch locations in Swiss white alpine sheep
NZ624269B (en) Method for the treatment of hypercholesterolemia
HK1210590B (en) Method for the treatment of hypercholesterolemia
Sur et al. Benzylideneacetophenone derivative alleviates arthritic symptoms via modulation of the MAPK signaling pathway
Helal et al. Analgesic Effect of Dexmedetomidine-Nalbuphine Combination vs. Dexmedetomidine Alone in Donkeys Undergoing Field Castration under Total Intravenous Anesthesia
Wei et al. Caloric restriction can ameliorate postoperative cognitive dysfunction by upregulating the expression of Sirt1, MeCP2 and BDNF in the hippocampal CA1 region of aged C57BL/6 mice
US20060019963A1 (en) Compounds
Amari et al. Comparison of Three Different Balanced Sedative-Anaesthetic Protocols in Captive Baboons (Papio hamadryas)
RU2256460C2 (ru) Способ лечения неспецифической бронхопневмонии у телят
Gupta Systemic sclerosis treated with dexamethasone pulse
Nagel et al. Efficacy and Safety of Lidocam Topical Gel (4% Lidocaine—0.3% Meloxicam) for Pain and Inflammation Management during Castration and Tail Docking in Piglets
Dakheel et al. Determine of Leishmaniasis among Libyan patients at University Hospital
Interlandi et al. Impact of Two Surgical Techniques for Umbilical Hernia Repair, With and Without Peritoneal Opening, on Pain Response, Sedation, and Oxidative Stress in Calves
US20190224187A1 (en) New use of isoquinoline derivatives for wound healing